Illumina, Inc 8-K, filed Feb 6, 2020
Illumina, Inc. (ILMN)
8-K
2020-02-06
For: 2020-02-04
View Original
Added on
April 12, 2026
About this 8-K
Illumina, Inc filed this 8-K on February 6, 2020, reporting on events of February 4, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 4, 2020

(Exact name of registrant as specified in its charter)
(Commission File Number)
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||||||
(Address of principal executive offices) (Zip code)
(858 ) 202-4500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
5.02(d)
On February 4, 2020 , the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and elected Scott Gottlieb, to serve on the Board beginning February 4, 2020. Dr. Gottlieb will stand for election at the Company’s 2020 annual meeting of stockholders to serve for a one-year term commencing with such meeting. There is no arrangement or understanding between Dr. Gottlieb and any other person pursuant to which he was selected as a director. In addition, Dr. Gottlieb is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933. Dr. Gottlieb will participate in the non-employee director compensation programs described under “Director Compensation” in the Company’s proxy statement filed on April 16, 2019.
A copy of the press release announcing the appointment of Dr. Gottlieb is attached as Exhibit 99.1 to this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ILLUMINA, INC. | ||||||||||||||||||||
| Date: | February 6, 2020 | By: | /s/ CHARLES E. DADSWELL | |||||||||||||||||
| Charles E. Dadswell | ||||||||||||||||||||
| Senior Vice President, General Counsel and Secretary | ||||||||||||||||||||
Exhibit Index
| Exhibit Number | Description | |||||||
| Press Release dated February 6, 2020 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors
SAN DIEGO, CA –February 6, 2020 -- Illumina, Inc. (NASDAQ: ILMN) announced today that Scott Gottlieb, M.D. has joined the company’s Board of Directors, effective February 4, 2020. Dr. Gottlieb is currently a special partner at the venture capital firm New Enterprise Associates (NEA) and a resident fellow at the American Enterprise Institute (AEI). From 2017 to 2019, he served as the 23rd commissioner of the Food and Drug Administration (FDA).
During his time at the FDA, Dr. Gottlieb helped make the regulatory process for the development and review of novel drug and medical devices more efficient, including the approval of the first gene-therapy-based cancer treatments. He advanced the FDA’s Oncology Center for Excellence and helped implement the 21st Century Cures Act to accelerate medical product development. He also presided over a record number of approvals for generic and new drugs and novel medical devices, and advanced other efforts to promote food safety, vaccinations, reduce smoking rates, and address opioid addiction.
Dr. Gottlieb previously served as the agency’s deputy commissioner for medical and scientific affairs, and as a senior adviser for medical technology to the FDA Commissioner. He also served as senior policy adviser to the administrator at the Centers for Medicare & Medicaid Services. Prior to joining the FDA as commissioner, he was a clinical assistant professor at New York University School of Medicine. Earlier, he was a practicing physician and hospitalist concurrently with his AEI work.
“I am excited to welcome Scott to Illumina’s Board of Directors,” said Francis deSouza, Illumina’s Chief Executive Officer. “Illumina will benefit from Scott’s expertise in healthcare and public policy as we work to accelerate the adoption and impact of genomics into the standard of care in oncology, reproductive health and other clinical areas.”
Dr. Gottlieb has a medical degree from Mount Sinai School of Medicine and completed his residency in internal medicine at the Mount Sinai Medical Center. He is an elected member of the National Academy of Medicine. He has a B.A. in economics from Wesleyan University.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Illumina, Inc.
Investors:
Jacquie Ross, CFA
858-255-5243
ir@illumina.com
or
Media:
Tina Amirkiai
858-882-6822
pr@illumina.com